YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The biosimilar Ustekinumab has been developed and manufactured by the company
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Aims to achieve CDMO sales of US$ 400 million by 2028
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Subscribe To Our Newsletter & Stay Updated
